TriangleNCT01550003 · CITED IN SOURCE DOCUMENTS
Pediatric Arthritis Study of Certolizumab Pegol
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2024-10-23
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48
Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study
Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2) * Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2) * Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA) * Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline * Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment) * If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m\^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response * If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose Exclusion Criteria: * Study participant has previously been exposed to more than 2 biologic agents * Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug * Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer * Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction * Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not) * Study participant has a history of systemic JIA, with or without systemic features * Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication * Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related) * Study participant has active uveitis or a history of active uveitis within the preceding 6 months * Study participant has current, chronic or recurrent clinically significant infections * Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening \[Visit 1\]), had a recent (within the 6 months prior to Screening \[Visit 1\]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 2 Years
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
- intervention Names
- Drug: Certolizumab Pegol (CZP)
- label
- Certolizumab Pegol
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Certolizumab Pegol
- description
- CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution. Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range. Reduced CZP regimen (after implementation of protocol amendments 4 and 5): * 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc); * 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc); * ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
- name
- Certolizumab Pegol (CZP)
- other Names
- Cimzia
- type
- DRUG
- arm Group Labels
- Certolizumab Pegol
- description
- CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution. Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range. Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9): * 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc); * 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc); * ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
- name
- Certolizumab Pegol (CZP)
- other Names
- Cimzia
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 193
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).
- measure
- Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
- time Frame
- Week 16
- description
- Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL.
- measure
- Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48
- time Frame
- Week 48
- description
- Number of participants with anti-CZP antibodies were reported.
- measure
- Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16
- time Frame
- Week 16
- description
- Number of participants with anti-CZP antibodies were reported.
- measure
- Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48
- time Frame
- Week 48
- description
- A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication.
- measure
- Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
- time Frame
- From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
- description
- An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure.
- measure
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study
- time Frame
- From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
- secondary Outcomes
- description
- PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by \>30%: * Number of joints with active arthritis * Number of joints with limitation of range of motion * Physician's Global Assessment of Disease Activity (using visual analog scale (VAS): 100mm; 0= very good, and 100= very poor) * CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score \[ 0= no disability to 3= very severe disability\]) * Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) * C-reactive protein (CRP)
- measure
- Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
- time Frame
- Week 16
- description
- PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by \>30%: * Number of joints with active arthritis * Number of joints with limitation of range of motion * Physician's Global Assessment (PGA) of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) * Childhood Health Assessment Questionnaire (CHAQ) (30 questions, 8 domains, scores for each domain are averaged to calculate total score \[ 0= no disability to 3= very severe disability\]) * Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) * CRP
- measure
- Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
- time Frame
- Week 16
- description
- PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by \>30%: * Number of joints with active arthritis * Number of joints with limitation of range of motion * Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) * CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score \[ 0= no disability to 3= very severe disability\]) * Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) * CRP
- measure
- Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
- time Frame
- Week 16
- description
- PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by \>30%: * Number of joints with active arthritis * Number of joints with limitation of range of motion * Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) * CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score \[ 0= no disability to 3= very severe disability\]) * Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) * CRP
- measure
- Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
- time Frame
- Week 16
Full study description
- brief Summary
- A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
- detailed Description
- The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits. If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-319743559ba2e0ab51a9
- requested nct id
- NCT01550003
- primary nct id
- NCT01550003
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 7aca162a9bb721a10115bc89c64868c53ea542fa569a9273e4a9bee9d1ce4f41
- payload
- application numbers
- BLA125160
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-319743559ba2e0ab51a9
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01550003
- occurrences
- context exact
- hritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis. Pediatric Patients: In the JIA with active polyarthritis study (NCT01550003), the mean trough plasma concentrations at Week 12 (steady-state) were 31.8 µg/mL, 27.9 µg/mL, and 36.8 µg/mL for patients weighing 10 to <20 kg, 20 to <40 kg,
- end
- 8345
- exact text
- NCT01550003
- start
- 8334
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/12/clinical_pharmacology/0
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 66794f0c1a2c7cd8a541304f9b5417e4605af27e083f90ac31744189de440c0c
- spl effective time
- 20260224
- spl set id
- b4c2c9dc-a0bb-4d64-a667-a67ebe88392d
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bf0c825642be0e01205a
- requested nct id
- NCT01550003
- primary nct id
- NCT01550003
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 02dee5b92b31bef38d576d259ee72a99c15a6411638bf5ac279544c985059415
- payload
- application numbers
- BLA125160
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bf0c825642be0e01205a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01550003
- occurrences
- context exact
- c exposure and extrapolation of the established efficacy of CIMZIA in RA patients. The efficacy of CIMZIA was also assessed in a multi-center, open-label study NCT01550003 in 193 patients 2 to 17 years of age with JIA with active polyarthritis with an inadequate response or intolerance to at least 1 DMARD (nonbiologic or biologic
- end
- 10995
- exact text
- NCT01550003
- start
- 10984
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/12/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- acd06e5b0f0323ed57d435cad16123c57128f6df0da1f617fd10a396080ff5d5
- spl effective time
- 20260224
- spl set id
- b4c2c9dc-a0bb-4d64-a667-a67ebe88392d
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e0adee0b8d9af4be1e87
- requested nct id
- NCT01550003
- primary nct id
- NCT01550003
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 3b5b7a88f46254dbc8abafaa034bcdfcf23b68fabc16ee550e8303212863d094
- payload
- application numbers
- BLA125160
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e0adee0b8d9af4be1e87
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01550003
- occurrences
- context exact
- hritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis. Pediatric Patients: In the JIA with active polyarthritis study (NCT01550003), the mean trough plasma concentrations at Week 12 (steady-state) were 31.8 µg/mL, 27.9 µg/mL, and 36.8 µg/mL for patients weighing 10 to <20 kg, 20 to <40 kg,
- end
- 5722
- exact text
- NCT01550003
- start
- 5711
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/12/pharmacokinetics/0
- source kind
- fda_spl_label
- source record id
- 4b984e6f-72ac-4fdc-e063-6394a90af105
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 63ad416930406b973917ad8da600583843df31251c1ab4cfdeeb45ec527a0f98
- spl effective time
- 20260224
- spl set id
- b4c2c9dc-a0bb-4d64-a667-a67ebe88392d
Preserved source evidence · Not medical advice